- Home
- LONA vs TLPH Comparison
LONA vs TLPH Comparison
Compare LONA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LONA | TLPH |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 70.3M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LONA | TLPH |
|---|---|---|
| Price | $5.67 | $1.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.33 | $3.13 |
| AVG Volume (30 Days) | ★ 455.8K | 148.3K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $0.69 |
| 52 Week High | $14.21 | $1.57 |
Technical Indicators
Market Signals| Indicator | LONA | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 35.90 |
| Support Level | $4.55 | $0.76 |
| Resistance Level | $6.13 | $1.13 |
| Average True Range (ATR) | 1.01 | 0.04 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 77.86 | 25.00 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.